Baker Bros. Advisors LP Galmed Pharmaceuticals Ltd. Transaction History

Baker Bros. Advisors LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$2.24 - $3.9 $414,236 - $721,215	-184,927 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$3.06 - $4.17 $62,570 - $85,268	-20,448 Reduced 9.96%	184,927 $575,000
Q3 2020 Nov 16, 2020	SELL	$3.46 - $5.69 $35,357 - $58,146	-10,219 Reduced 4.74%	205,375 $725,000
Q4 2018 Feb 13, 2019	SELL	$6.59 - $14.47 $715,015 - $1.57 Million	-108,500 Reduced 33.48%	215,594 $1.47 Million
Q3 2018 Nov 14, 2018	SELL	$10.55 - $15.28 $3.29 Million - $4.77 Million	-312,046 Reduced 49.05%	324,094 $4.4 Million

Q2 2018 Aug 14, 2018	BUY	$5.04 - $17.96 $3.21 Million - $11.4 Million	636,140 New	636,140 $7.57 Million

Ticker GLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,088,400
Market Cap $7.02M
Description
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or t...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.